<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195919</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_ESRD_I</org_study_id>
    <nct_id>NCT04195919</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients</brief_title>
  <official_title>A Clinical Study to Investigate the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to investigate the pharmacokinetics/ pharmacodynamics and
      safety/tolerability of Evogliptin in hemodialysis patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>1day(15day) pre-dose (0), 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48 hour post-dose</time_frame>
    <description>Area Under the plasma Concentration versus time curve(AUClast) of Evogliptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>1day(15day) pre-dose (0), 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48 hour post-dose</time_frame>
    <description>Peak Plasma Concentration(Cmax) of Evogliptin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis patients(MDRD-eGFR ≤ 15 mL/min/1.73m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control(MDRD-eGFR ≥ 90 mL/min/1.73m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin 5mg</intervention_name>
    <description>Participants receive Single oral administration of Evogliptin 5mg on day1</description>
    <arm_group_label>Group2</arm_group_label>
    <other_name>Suganon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin 5mg</intervention_name>
    <description>Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)
Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period</description>
    <arm_group_label>Group1</arm_group_label>
    <other_name>Suganon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who aged 20 to 80 at the time of screening

          2. Subjects with 50.0kg≤Body Weight≤90.0kg and 18.0kg/m2≤BMI≤27.0kg/m2

          3. Subjects who meet the following kidney functions

               -  group1(hemodialysis patients): MDRD-eGFR ≤ 15 mL/min/1.73m2

               -  group2(helthy control): MDRD-eGFR ≥ 90 mL/min/1.73m2

        Exclusion Criteria:

          1. Subjects who have a uncontrolled or unstable disease such as liver, nervous system,
             immune system, respiratory system, endocrine system or blood / tumor disease,
             cardiovascular disease, mental disorders (mood disorder, obsessive compulsive
             disorder, etc.) or history

          2. Subjects who have a gastrointestinal disease (such as Crohn's disease, ulcers, acute
             or chronic pancreatitis, etc.) or history of gastrointestinal surgery (except simple
             appendectomy or hernia surgery) that may affect the absorption of the test drug.

          3. Subjects with a history of significant hypersensitivity reaction such as anaphylaxis
             or angioedema to DPP-IV inhibitors

          4. Subjects who have AST (SGOT) and ALT (SGPT) greater than 1.5 times the upper limit of
             normal range, at the time of screening test including additional tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yon-Su Kim, M.D., Ph.D.</last_name>
    <phone>02-2072-2264</phone>
    <email>yonsukim@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

